Table 1.
Incidence Rates of Herpes Zoster by Diabetes and Concomitant Immune-Compromised Status, 2005–2009
| Diabetic Individuals |
Nondiabetics Individuals |
Difference |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Herpes Zoster Cases | Person- Years (PY) | Cases/ 1000 PY | 95% Confidence Interval [CI]* | Herpes Zoster Cases | Person- Years (PY) | Cases/ 1000 PY | 95% CI* | Incidence Rate Ratio | 95% CI** | |
| Total study population | ||||||||||
| Enrollees in group | 61 142 | 7 681 336 | 7.96 | (7.90–8.02) | 359 373 | 80 266 547 | 4.48 | (4.46–4.49) | 1.78 | (1.76–1.79) |
| Sex | ||||||||||
| Females | 35 071 | 3 826 046 | 9.17 | (9.07–9.26) | 224 735 | 43 431 997 | 5.17 | (5.15–5.20) | 1.77 | (1.75–1.79) |
| Males | 26 071 | 3 855 290 | 6.76 | (6.68–6.85) | 134 638 | 36 834 550 | 3.66 | (3.64–3.68) | 1.85 | (1.83–1.87) |
| Age group | ||||||||||
| 18–49 years | 12 441 | 2 464 386 | 5.05 | (4.96–5.14) | 169 277 | 51 819 510 | 3.27 | (3.25–3.28) | 1.55 | (1.52–1.57) |
| 50–59 years | 22 284 | 2 821 550 | 7.90 | (7.79–8.00) | 104 908 | 17 041 888 | 6.16 | (6.12–6.19) | 1.28 | (1.26–1.30) |
| 60–64 years | 9619 | 993 001 | 9.69 | (9.49–9.88) | 31 838 | 4 396 777 | 7.24 | (7.16–7.32) | 1.34 | (1.31–1.37) |
| ≥65 years | 16 798 | 1 402 399 | 11.98 | (11.80–12.16) | 53 350 | 7 008 371 | 7.61 | (7.55–7.68) | 1.57 | (1.55–1.60) |
| Immune competent | ||||||||||
| Enrollees in group | 56 261 | 7 309 166 | 7.70 | (7.63–7.76) | 335 809 | 78 133 941 | 4.30 | (4.28–4.31) | 1.79 | (1.78–1.81) |
| Sex | ||||||||||
| Females | 32 308 | 3 632 648 | 8.89 | (8.80–8.99) | 209 521 | 42 154 331 | 4.97 | (4.95–4.99) | 1.79 | (1.77–1.81) |
| Males | 23 953 | 3 676 518 | 6.52 | (6.43–6.60) | 126 288 | 35 979 610 | 3.51 | (3.49–3.53) | 1.86 | (1.83–1.88) |
| Age group | ||||||||||
| 18–49 years | 11 670 | 2 394 113 | 4.87 | (4.79–4.96) | 162 206 | 50 979 189 | 3.18 | (3.17–3.20) | 1.53 | (1.50–1.56) |
| 50–59 years | 20 682 | 2 694 694 | 7.68 | (7.57–7.78) | 97 670 | 16 397 987 | 5.96 | (5.92–5.99) | 1.29 | (1.27–1.31) |
| 60–64 years | 8803 | 933 587 | 9.43 | (9.23–9.63) | 28 881 | 4 169 442 | 6.93 | (6.85–7.01) | 1.36 | (1.33–1.39) |
| ≥65 years | 15 106 | 1 286 772 | 11.74 | (11.55–11.93) | 47 052 | 6 587 323 | 7.14 | (7.08–7.21) | 1.64 | (1.61–1.67) |
| Immune compromised | ||||||||||
| Enrollees in group | 4881 | 372 169 | 13.12 | (12.75–13.49) | 23 564 | 2 132 606 | 11.05 | (10.91–11.19) | 1.19 | (1.15–1.22) |
| Sex | ||||||||||
| Females | 2763 | 193 398 | 14.29 | (13.76–14.83) | 15 214 | 1 277 666 | 11.91 | (11.72–12.10) | 1.20 | (1.15–1.25) |
| Males | 2118 | 178 772 | 11.85 | (11.35–12.36) | 8350 | 854 940 | 9.77 | (9.56–9.98) | 1.21 | (1.16–1.27) |
| Age group | ||||||||||
| 18–49 years | 771 | 70 273 | 10.97 | (10.21–11.77) | 7071 | 840 321 | 8.41 | (8.22–8.61) | 1.30 | (1.21–1.40) |
| 50–59 years | 1602 | 126 856 | 12.63 | (12.02–13.26) | 7238 | 643 902 | 11.24 | (10.98–11.50) | 1.12 | (1.06–1.19) |
| 60–64 years | 816 | 59 414 | 13.73 | (12.81–14.71) | 2957 | 227 335 | 13.01 | (12.54–13.49) | 1.06 | (0.98–1.14) |
| ≥65 years | 1692 | 115 627 | 14.63 | (13.94–15.35) | 6298 | 421 048 | 14.96 | (14.59–15.33) | 0.98 | (0.93–1.03) |
* 95% confidence interval (CI) was based on Poisson distribution.
** 95% CI of incidence rate ratio was based on Mantel–Haenszel combined estimate.